AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10212042 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 44
Study 10212042 — intervention group
Group type: COMPARATOR
Intervention: Both IA and PE
Number of subjects: 44
Study 7840170 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 7
Study 7840170 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 7
Study 2090834 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 674624 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g iopanoic acid administered over 6 hours (0.5 g/hour)
Number of subjects: 168
Study 674624 — intervention group
Group type: COMPARATOR
Intervention: 3 g iopanoic acid administered in a single dose
Number of subjects: 168
Study 31088784 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (HG)
Number of subjects: 2766
Study 31088784 — intervention group
Group type: COMPARATOR
Intervention: No headgear (NoHG)
Number of subjects: 2766
Study 29396205 — intervention group
Group type: EXPERIMENTAL
Intervention: DM + PAD
Number of subjects: 62
Study 29396205 — intervention group
Group type: COMPARATOR
Intervention: DM without PAD
Number of subjects: 62
Study 27295465 — intervention group
Group type: EXPERIMENTAL
Intervention: Media coverage of wise interventions
Number of subjects: 0
Study 27295465 — intervention group
Group type: COMPARATOR
Intervention: Cautious language introduced to media coverage
Number of subjects: 0
Study 23682041 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal endocoil (CEC)
Number of subjects: 30
Study 23682041 — intervention group
Group type: COMPARATOR
Intervention: Prostate endocoil (PEC)
Number of subjects: 30
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese before stroke
Number of subjects: 3173
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight before stroke
Number of subjects: 3173
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus before stroke
Number of subjects: 3173
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking before stroke
Number of subjects: 3173
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity before stroke
Number of subjects: 3173
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest physical function quartile before stroke
Number of subjects: 3173
Study 23869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Current hormone use before stroke
Number of subjects: 3173
Study 20625738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib and erlotinib treatment
Number of subjects: 23
Study 18928103 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzhong Yiqi Pill (BYP) combined with imodium
Number of subjects: 80
Study 18928103 — intervention group
Group type: COMPARATOR
Intervention: Imodium (loperamide hydrochloride)
Number of subjects: 80
Study 15920209 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus interview
Number of subjects: 197
Study 15920209 — intervention group
Group type: COMPARATOR
Intervention: Brochure plus interview
Number of subjects: 197
Study 15920209 — intervention group
Group type: COMPARATOR
Intervention: Routine preanesthetic interview
Number of subjects: 197
Study 12794408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure at 0 cm H(2)O
Number of subjects: 12
Study 12794408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure at 5 cm H(2)O
Number of subjects: 12
Study 12794408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure at 10 cm H(2)O
Number of subjects: 12
Study 12794408 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing with 0 cm H(2)O continuous positive airway pressure
Number of subjects: 12
Study 10934092 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via face mask 0.25 mg daily
Number of subjects: 481
Study 10934092 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via face mask 0.25 mg twice daily
Number of subjects: 481
Study 10934092 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via face mask 0.5 mg twice daily
Number of subjects: 481
Study 10934092 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via mouthpiece 0.25 mg twice daily
Number of subjects: 481
Study 10934092 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension via mouthpiece 1.0 mg daily
Number of subjects: 481
Study 10934092 — intervention group
Group type: COMPARATOR
Intervention: Budesonide inhalation suspension via face mask or mouthpiece
Number of subjects: 481
Study 8939176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium pretreatment
Number of subjects: 8
Study 8240462 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic-ginkgo combination product (Allium plus)
Number of subjects: 43
Study 8240462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3816230 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 + 1 mg PG pessary
Number of subjects: 39
Study 3816230 — intervention group
Group type: COMPARATOR
Intervention: RU486 alone
Number of subjects: 39
Study 3816230 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 + 2 mg Gemeprost
Number of subjects: 39
Study 3816230 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 + PG
Number of subjects: 39
Study 30208854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 intervention: physical activity assessment during Nephrology clinical visit, brief counseling at pre-dialysis education, and physical activity wearable.
Number of subjects: 96
Study 30208854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 intervention: Group 1 components plus a referral to a free, EIM practitioner-led group exercise program over 16 weeks (8-week core intervention; 8-week follow up).
Number of subjects: 96
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 25 mg
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 50 mg
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 100 mg
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 200 mg
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 200 mg (four 50 mg tablets)
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 600 mg
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 50 mg (children)
Number of subjects: 446
Study 27472949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 100 mg (children)
Number of subjects: 446
Study 23774460 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (mild)
Number of subjects: 9687
Study 23774460 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (moderate-to-severe)
Number of subjects: 9687
Study 23774460 — intervention group
Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 9687
Study 22178258 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate breakfast (LCb)
Number of subjects: 193
Study 22178258 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate and protein breakfast (HCPb)
Number of subjects: 193
Study 20736298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,250 mg/day) plus capecitabine (2,000 mg/m2)
Number of subjects: 399
Study 20736298 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy (2,500 mg/m2)
Number of subjects: 399
Study 20736298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (considering crossover)
Number of subjects: 399
Study 18174476 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (3H group)
Number of subjects: 46
Study 18174476 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (4H group)
Number of subjects: 46
Study 18174476 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 15836977 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term opioid administration in chronic pain patients
Number of subjects: 4
Study 15836977 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term opioid administration in chronic pain patients
Number of subjects: 4
Study 15836977 — intervention group
Group type: COMPARATOR
Intervention: Pain-free control subjects
Number of subjects: 4
Study 15836977 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic non-malignant pain subjects
Number of subjects: 4
Study 12740447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 7
Study 12740447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10494053 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pressure differential valves
Number of subjects: 344
Study 10494053 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta valves
Number of subjects: 344
Study 10494053 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbis Sigma valves
Number of subjects: 344
Study 10494053 — intervention group
Group type: COMPARATOR
Intervention: Control group (last quarter patients)
Number of subjects: 344
Study 9063208 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental irrigation with 15 mL of a 100‐mg/mL tetracycline solution
Number of subjects: 12
Study 9063208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline‐loaded fiber after mechanical instrumentation
Number of subjects: 12
Study 9063208 — intervention group
Group type: COMPARATOR
Intervention: Supragingival and subgingival scaling with an ultrasonic scaler (Control)
Number of subjects: 12
Study 9063208 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatment modalities
Number of subjects: 12
Study 1891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine substitution with behavioral therapy
Number of subjects: 403
Study 1891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine substitution (nicotine patches)
Number of subjects: 403
Study 1891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 403
Study 1891488 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual versus fixed dose of nicotine patches
Number of subjects: 403
Study 6382936 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml
Number of subjects: 50
Study 6382936 — intervention group
Group type: COMPARATOR
Intervention: meglumine iothalamate 280 mg I/ml
Number of subjects: 50
Study 31658293 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml dye injection
Number of subjects: 7
Study 31658293 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml dye injection
Number of subjects: 7
Study 30002088 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 0.5 mL 0.1% nitroglycerin
Number of subjects: 188
Study 30002088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 26698408 — intervention group
Group type: COMPARATOR
Intervention: HABIT (bimanual therapy)
Number of subjects: 20
Study 26698408 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT + Tactile training (HABIT+T)
Number of subjects: 20
Study 25179038 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable ECG lead wires
Number of subjects: 51
Study 22169884 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 19
Study 22169884 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 19
Study 22169884 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 19
Study 22169884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20709727 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a daylong group smoking cessation workshop
Number of subjects: 45
Study 20709727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazard modeling
Number of subjects: 45
Study 17334548 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution during surgery (Group SS)
Number of subjects: 50
Study 17334548 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil during surgery (Group 5-FU1)
Number of subjects: 50
Study 17334548 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 50
Study 17334548 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil with multiple injections (Group 5-FU3)
Number of subjects: 50
Study 15750368 — intervention group
Group type: EXPERIMENTAL
Intervention: CV4
Number of subjects: 20
Study 15750368 — intervention group
Group type: COMPARATOR
Intervention: CV4 sham
Number of subjects: 20
Study 15750368 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 11874443 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (troglitazone)
Number of subjects: 28
Study 11874443 — intervention group
Group type: COMPARATOR
Intervention: Control (MET added to SU monotherapy)
Number of subjects: 28
Study 10468751 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific dietary regimen recommended and corrected according to a comprehensive metabolic evaluation (Group 1)
Number of subjects: 242
Study 10468751 — intervention group
Group type: COMPARATOR
Intervention: General dietary measures with minimal metabolic screening (Group 2)
Number of subjects: 242
Study 8688984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 92
Study 8688984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 92
Study 1282609 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT (nitrates) 80-120 mg/day
Number of subjects: 30
Study 1282609 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF (nifedipine) 40-60 mg/day
Number of subjects: 30
Study 1282609 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS (nisoldipine) 10-20 mg/day
Number of subjects: 30
Study 6428511 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg/day (subcutaneous, continuous infusion or injections every six hours)
Number of subjects: 4
Study 6428511 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 12 mg/day (subcutaneous, continuous infusion)
Number of subjects: 4
Study 6428511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous, continuous infusion or injections every six hours)
Number of subjects: 4
Study 31509028 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx‐001 followed by four cycles of a platinum doublet, and then alternating cycles of RRx‐001 and single agent platinum until progression
Number of subjects: 120
Study 31509028 — intervention group
Group type: COMPARATOR
Intervention: Platinum doublet
Number of subjects: 120
Study 29402815 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pharyngeal surface anesthesia
Number of subjects: 11
Study 29402815 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 11
Study 26502371 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA treatment in donor and recipient (DR group)
Number of subjects: 26
Study 26502371 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient ALA treatment
Number of subjects: 26
Study 26502371 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study 25329228 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-enriched supplementation (2.2 g EPA)
Number of subjects: 69
Study 25329228 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric supplementation
Number of subjects: 69
Study 22265753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8-week MBCT-based eating intervention)
Number of subjects: 26
Study 20014183 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk thistle (MT)
Number of subjects: 50
Study 20014183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18550438 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 18550438 — intervention group
Group type: EXPERIMENTAL
Intervention: SERT gene promoter polymorphism 5‐HTTLPR
Number of subjects: 0
Study 18550438 — intervention group
Group type: EXPERIMENTAL
Intervention: SERT expression in intestinal mucosa
Number of subjects: 0
Study 16172356 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized nasal douche
Number of subjects: 200
Study 16172356 — intervention group
Group type: COMPARATOR
Intervention: Nasal lavages with isotonic sodium chloride solution
Number of subjects: 200
Study 12154423 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 18
Study 12154423 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 18
Study 12154423 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 18
Study 9493671 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime mechanical ventilation (dMV)
Number of subjects: 34
Study 9493671 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal mechanical ventilation (nMV)
Number of subjects: 34
Study 7536072 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 5 micrograms/kg sc daily for 8 days and G-CSF 16 micrograms/kg i.v. four times daily after autologous BMT
Number of subjects: 44
Study 7536072 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF (250 micrograms/m2 sc daily for 8 days or 125 micrograms/m2 sc twice daily for 8 days) and GM-CSF (250 micrograms/m2 i.v. four times daily) after autologous BMT
Number of subjects: 44
Study 7536072 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF after autologous BMT
Number of subjects: 44
Study 3299684 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovectomy (n = 15)
Number of subjects: 30
Study 3299684 — intervention group
Group type: COMPARATOR
Intervention: No synovectomy (n = 15)
Number of subjects: 30
Study 31995222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's hug
Number of subjects: 135
Study 31995222 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 135
Study 31995222 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 28783871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (escalated from 0.25 to 2 mg over 14 days)
Number of subjects: 124
Study 28783871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 124
Study 28783871 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (administered on days 2 and 17)
Number of subjects: 124
Study 27599229 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing with Standard Management of Depression (MI-SMD)
Number of subjects: 168
Study 27599229 — intervention group
Group type: COMPARATOR
Intervention: Standard Management of Depression (SMD) alone
Number of subjects: 168
Study 24549027 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND) rich in whole-grain rye and wheat, n=96
Number of subjects: 166
Study 24549027 — intervention group
Group type: COMPARATOR
Intervention: Control diet, n=70
Number of subjects: 166
Study 24549027 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 166
Study 24549027 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plasma AR concentration
Number of subjects: 166
Study 23073583 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 80
Study 23073583 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS rTMS
Number of subjects: 80
Study 23073583 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 80
Study 23073583 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 80
Study 20535041 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosegmental transpedicular fixation
Number of subjects: 85
Study 20535041 — intervention group
Group type: COMPARATOR
Intervention: Biosegmental transpedicular fixation
Number of subjects: 85
Study 18958837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (including glucose-insulin-potassium (GIK) approaches and non-GIK approaches)
Number of subjects: 0
Study 18958837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy in critically ill non-ACS patients
Number of subjects: 0
Study 18958837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing and planned trials of insulin in ACS patients
Number of subjects: 0
Study 16840576 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention group (3 sessions per week for 13 weeks)
Number of subjects: 26
Study 16840576 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention group
Number of subjects: 26
Study 16840576 — intervention group
Group type: COMPARATOR
Intervention: Control group (supervised stretching program)
Number of subjects: 26
Study 14687355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1,000 IU/d)
Number of subjects: 65
Study 14687355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 10879665 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide dialyzer
Number of subjects: 18
Study 10879665 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan dialyzer
Number of subjects: 18
Study 10879665 — intervention group
Group type: COMPARATOR
Intervention: Polycarbonate dialyzer
Number of subjects: 18
Study 10879665 — intervention group
Group type: EXPERIMENTAL
Intervention: All dialyzers
Number of subjects: 18
Study 8836309 — intervention group
Group type: EXPERIMENTAL
Intervention: Posatirelin 10 mg/ml, administered intramuscularly once a day for 12 weeks
Number of subjects: 0
Study 8836309 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered intramuscularly once a day for 12 weeks
Number of subjects: 0
Study 8836309 — intervention group
Group type: EXPERIMENTAL
Intervention: Posatirelin 10 mg/ml
Number of subjects: 0
Study 8836309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8258839 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard management with systemic hypothermia to 32 to 33 degrees C (n = 24)
Number of subjects: 46